Evaluation of chronic diseases in elderly patients
China Elderly Comorbidity Medical Database
This study looks at older adults with multiple chronic diseases to see how we can better identify risks and improve their care over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4100 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | Beijing Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06316544 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to evaluate and provide early warnings for elderly patients suffering from multiple chronic diseases such as coronary artery disease, hypertension, diabetes, osteoporosis, and COPD. It seeks to identify effective evaluation methods and key indicators that influence adverse events in this population, considering their high individual heterogeneity. Participants will be followed up at intervals of 1, 3, 6, 9, and 12 months to gather information on adverse events and improve medical decision-making for complex cases. The study addresses the challenges posed by the high prevalence of comorbidities among the elderly, which complicates treatment and resource allocation.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 65 and older with at least one of the specified chronic diseases.
Not a fit: Patients without any of the targeted chronic diseases or those younger than 65 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and outcomes for elderly patients with multiple chronic conditions.
How similar studies have performed: Other studies focusing on elderly comorbidities have shown promise in improving patient outcomes, indicating that this approach is both relevant and potentially beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 65 years old; * At least one of hypertension, type 2 diabetes, coronary heart disease, osteoporosis, chronic obstructive pulmonary disease (COPD). Coronary heart disease: Heart disease caused by stenosis or occlusion of the official cavity caused by coronary atherosclerosis, resulting in myocardial ischemia, hypoxia or necrosis. This includes chronic myocardial ischemic syndrome (stable angina, ischemic cardiomyopathy, and occult coronary heart disease) and acute coronary syndrome (unstable angina and acute myocardial infarction). type 2 diabetes: HbA1c is greater than 6.5% or fasting blood glucose is greater than 126mg/dL (7.0mmol/L), and fasting is defined as no calorie intake for at least 8 hours; Or oral glucose tolerance test (OGTT) with blood glucose levels greater than 200mg/dL (11.1mmol/L) within 2 hours; Or clinical manifestations of hyperglycemia, random blood glucose greater than 200mg/dL (11.1mmol/L); Or is/has been using hypoglycemic drugs/insulin therapy. Hypertension: Twice random blood pressure, systolic blood pressure (SBP) higher than 140mmHg and/or diastolic blood pressure (DBP) higher than 90mmHg; Or is/has been taking antihypertensive medication. Chronic obstructive pulmonary disease: There are COPD related risk factors and respiratory symptoms, and lung function suggests that there is still airflow restriction after inhaling bronchodilators. The first second forced expiratory volume/forced vital capacity (FEV1/FVC) is less than 0.7. Osteoporosis: A metabolic bone disease characterized by decreased bone mass, destruction of bone tissue microstructure, increased bone fragility, and susceptibility to fractures. The diagnostic criteria are as follows: 1. A history of brittle fractures; 2. When there is no fracture, relying on dual energy X-ray absorption examination method: when measuring the axial bone density or the bone density T value of the hip or distal 1/3 of the radius is less than -2.5, it can be considered as osteoporosis. Exclusion Criteria: * Late stage malignant tumors, expected survival time less than 3 months; * Completely disabled and unable to communicate; * Unable to cooperate with follow-up.
Where this trial is running
Beijing, Beijing
- Beijing Friendship Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Bingbing Ke, Dr
- Email: 1017120710@qq.com
- Phone: 15510286857
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.